IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Acquires 11,773 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 11,773 shares of the stock in a transaction dated Tuesday, May 6th. The shares were purchased at an average cost of $1.15 per share, for a total transaction of $13,538.95. Following the completion of the purchase, the insider owned 150,916 shares in the company, valued at approximately $173,553.40. This represents a 8.46% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

IRIDEX Stock Up 29.4%

NASDAQ:IRIX opened at $0.88 on Thursday. IRIDEX Corporation has a 52 week low of $0.61 and a 52 week high of $1.65. The stock has a market capitalization of $15.46 million, a PE ratio of -4.40 and a beta of 0.67. The stock’s 50-day moving average price is $0.73 and its 200-day moving average price is $0.95.

IRIDEX (NASDAQ:IRIX) last announced its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The company had revenue of $12.57 million during the quarter, compared to analysts’ expectations of $13.59 million. Sell-side analysts expect that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Institutional Trading of IRIDEX

A number of institutional investors have recently made changes to their positions in IRIX. Weber Capital Management LLC ADV purchased a new stake in shares of IRIDEX during the second quarter worth approximately $206,616. United Capital Financial Advisors LLC acquired a new position in IRIDEX in the 2nd quarter valued at $41,000. Diversify Advisory Services LLC purchased a new position in IRIDEX in the 2nd quarter valued at $30,000. Diversify Wealth Management LLC purchased a new position in IRIDEX in the 1st quarter valued at $35,000. Finally, Bank of New York Mellon Corp acquired a new stake in IRIDEX during the 2nd quarter worth $29,000. 20.10% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, IRIDEX currently has a consensus rating of “Hold” and a consensus price target of $3.00.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.